

# The surface proteomic profile of serum extracellular vesicles as a diagnostic and prognostic tool in breast cancer

Giada Corti<sup>1</sup>, Rene Buchet<sup>2</sup>, Andrea Magrini<sup>3</sup>,  
Pietro Ciancaglini<sup>4</sup>, Saida Mebarek<sup>2</sup> and Massimo Bottini<sup>1,5</sup>

The diagnosis of breast cancer in the early stage is essential for a favorable prognosis. Extracellular vesicles isolated from body fluids have a central role in breast cancer development due to their biochemical components. Among the biochemical components, surface proteins mediate vesicle interactions with elements of the extracellular milieu, the extracellular matrix, and neighboring cells. The identification of specific surface proteomic profile has been regarded as an easy and reproducible means to define cancer parameters, identify markers for a diagnosis, and determine targets for therapeutical treatments. In this review, we will focus on annexins, tetraspanins, integrins, immune checkpoint proteins, and growth factor receptors that have been identified on the surface of extracellular vesicles isolated from the serum of patients with breast cancer and that have been found to be relevant diagnostic and prognostic biomarkers.

## Addresses

<sup>1</sup> Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

<sup>2</sup> Université Lyon 1, ICBMS UMR CNRS 5246, UFR Biosciences, 69 622 Villeurbanne Cedex, France

<sup>3</sup> Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy

<sup>4</sup> Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto -Universidade de São Paulo, 14040-900 Ribeirão Preto, Brazil

<sup>5</sup> Sanford Burnham Prebys, La Jolla, CA 92037, USA

Corresponding author: Bottini, Massimo ([massimo.bottini@uniroma2.it](mailto:massimo.bottini@uniroma2.it), [mbottini@sbdiscoversy.org](mailto:mbottini@sbdiscoversy.org))

**Current Opinion in Physiology** 2024, **37**:100734

This review comes from a themed issue on **Advances in EV Biology, Tech, Dis and Medicine**

Edited by **Susmita Sahoo, Benedetta Bussolati and Navneet Dogra**

Available online 12 December 2023

<https://doi.org/10.1016/j.cophys.2023.100734>

2468–8673/© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Introduction

Breast cancer is the most diagnosed cancer in females across the globe [1]. Even though breast cancer mortality has been steadily reducing in recent years, there is still a wide disparity between the prognosis of women diagnosed with early-stage breast cancer compared with those diagnosed with metastatic breast cancer [1].


Extracellular vesicles are lipid bilayer-delimited particles released by all cell types to carry out diverse functions, including remove unnecessary molecules from the cells' cytosol and plasma membrane, deliver information cargoes into target cells, and initiate biomineralization (Figure 1) [2,4,5]. Different classes of extracellular vesicles (e.g. exosomes, microvesicles, and apoptotic bodies) can be detected in cancer patients' tissues and body fluids (e.g. blood, urine, saliva, and lymphatic drainage fluid) where some of them are a source of biomarkers clinically valuable in providing insight into patients' diagnosis, prognosis, and treatment response [6]. The secretion of extracellular vesicles from breast cancer cells can trigger metastasis, and/or stimulate the tumoral activity by the transfer of nucleic acids and proteins from the extracellular vesicles' lumen to healthy cells [5] (Figure 1). The interactions between extracellular vesicles and their target cells are triggered by their external membrane components [5]. The extracellular vesicles' membrane proteins can be potential biomarkers, aiming to achieve benefits in breast cancer diagnosis, prognosis, monitoring, and treatment [7]. In this review, we will focus on annexins, tetraspanins, integrins, immune checkpoint proteins, and growth factor receptors that have been recently identified on the surface of extracellular vesicles isolated from the serum of breast cancer patients and that have been found to be relevant diagnostic and prognostic biomarkers.

## Surface proteins of serum extracellular vesicles as breast cancer biomarkers

### Tetraspanins

Tetraspanins are type-III transmembrane proteins expressed on both the plasma and intracellular membranes where they form microdomains involved in membrane trafficking and fusion, as well as cell motility and signaling [8,9]. Tetraspanins are also distributed on the extracellular vesicles' membrane where they initiate

Figure 1



The extracellular vesicles' surface proteins as diagnostic and prognostic biomarkers in breast cancer. **(a)** Extracellular vesicles have been divided into three major classes (e.g. exosomes, microvesicles, and apoptotic bodies) based on their biogenesis process and size [2]. **(b)** Extracellular vesicles harbor the complete set of biochemical components needed to carry out their functions [2]. Surface proteins enable extracellular vesicles to interact with elements of the extracellular matrix, the extracellular milieu, and neighboring cells [3]. By doing so, surface proteins mediate physiologic and pathologic processes, and have been regarded as clinically valuable biomarkers [4].

vesicle docking and uptake [10]. Proteomics indicates that cluster of differentiation 82 (CD82) [11] and Rhesus blood group (CD151) [12] were significantly enriched on the surface of extracellular vesicles derived from the serum of breast cancer patients than that of healthy individuals, suggesting possible diagnostic biomarkers (Table 1). Serum level of extracellular vesicle CD82 increased with breast cancer malignancy [11]. The treatment of MDA-MB-231 (highly invasive) and MDA-MB-468 cells (scarcely invasive) with CD151-devoid extracellular vesicles decreased cell motility, suggesting that CD151-expressing extracellular vesicles promoted the migration of breast cancer cells, regardless of their invasiveness, and might be used as a therapeutic target (Table 1) [12].

### Annexins

Annexins are  $\text{Ca}^{2+}$ /phospholipid-binding proteins that are involved in exocytosis, membrane repair, and apoptosis [13]. In cells, annexins are mostly cytosolic, but they were also found inside organelles as well as on the plasma membrane's leaflets [14,15]. Similarly, annexins were found simultaneously in different locations in extracellular vesicles [16].

Extracellular vesicles from breast cancer cell lines contain annexin A2 (AnxA2) [17]. The AnxA2 amount in extracellular vesicles correlated positively with cell invasiveness *in vitro*, and AnxA2-positive extracellular vesicles induced angiogenesis and promoted metastasis *in vivo* [17]. A study based on race-derived patient cohorts found that the serum level of extracellular vesicle AnxA2 was significantly higher in breast cancer patients than in healthy individuals and was associated with

tumor grade and poor overall survival (Table 1) [18]. The serum level of extracellular vesicle AnxA2 was also higher in triple-negative breast cancer (TNBC) than in other cancer subtypes (human epidermal growth factor receptor 2 [HER2<sup>+</sup>] and estrogen receptor [ER<sup>+</sup>]), and it was higher in African-American than in Caucasian-American patients with TNBC and correlated with tumor grade [18]. Thus, extracellular vesicle AnxA2 could be exploited as a diagnostic and prognostic marker of TNBC in African-descent women. Studies to assess the relationship of extracellular vesicle AnxA2 with other ethnicities and breast cancer subtypes are warranted.

Extracellular vesicle annexin A6 (AnxA6) mediated the prometastatic capacity of neoadjuvant chemotherapy [19]. The effects of neoadjuvant chemotherapy on the plasma level of extracellular vesicle AnxA6 were assessed in a small cohort (n = 6 including IA, IIB, and IIIA stages) of breast cancer patients undergoing neoadjuvant therapy (Table 1). The plasma level of extracellular vesicle AnxA6 increased at mid-treatment compared with pretreatment levels [19]. Notably, at the end of the therapy, and before curative operation, the level of extracellular vesicle AnxA6 decreased in the patients (n = 5) who achieved a complete or partial response, while it increased in one patient with no response. Thus, extracellular vesicle AnxA6 could be exploited as a predictive marker of metastasis and an outcome marker after neoadjuvant chemotherapy.

### Integrins

Integrins are type-I transmembrane proteins mediating several key processes, including cell-cell and cell-extracellular matrix interactions and signal transduction [20]. They are

Table 1

## Surface protein markers found in extracellular vesicles extracted from fluids of human patients or from cancer cells.

Isolation method	Fluid	Patients	Breast cancer cell lines	Markers	Ref.
- ExoQuick kit - UC (1500g, 30 min) - UC (1500g, 5 min)	Serum	Breast cancer patients (80) Patients with benign breast diseases (80) Healthy individuals (80)		CD82 diagnostic	[11]
- UF (0,22 $\mu$ m) - UC [150,000g, 3 h (x2)] - UC (1000g, 10 min) - UC (10,000g, 30 min) - UF (0,22 $\mu$ m) - UC (100,000g, 2 h) - UC (300g, 10 min) - UC (16,500g, 20 min) - UF (0,2 $\mu$ m) - UC (120,000g, 70 min) - UC (2000g, 30 min) - Incubation with total exosome isolation reagent - UC (10,000g, 10 min) - UC 134,000g, 70 min (x2)	Serum	TNBC patients (30) Healthy individuals (37)  Breast cancer patients [TNBC (58), ER <sup>+</sup> (50), HER2 <sup>+</sup> (59)] Healthy individuals (68)	MDA-MB-468 MDA-MD-231  MDA-MD-231	CD151 diagnostic, potentially therapeutic  AnxA2 diagnostic, prognostic	[12]  [17]
- UC (1600g, 15 min) - UC (100,000g, 70 min) - UC (355g, 10 min) - UC (1422g, 15 min) - UC (7199g, 15 min) - UF (0,45 $\mu$ m) - UC (100,00g, 90 min) in sucrose - UC (110,00g, 12 h) in sucrose - SEC - UC (500g, 10 min) - UC (12,000g, 20 min) - UC (100,000g, 70 min) - UC (300g) - UC (3000g) - UF (0,45 $\mu$ m) - UC (110,000g, 80 min) - UF (0,2 $\mu$ m) - UC (110,000g, 75 min)	Plasma	Breast cancer patients (6)		AnxA6 prognostic Integrins $\alpha_v$ , $\beta_1$ prognostic	[19]  [25]
- UC (1600g, 15 min) - UC (100,000g, 70 min) - UC (355g, 10 min) - UC (1422g, 15 min) - UC (7199g, 15 min) - UF (0,45 $\mu$ m) - UC (100,00g, 90 min) in sucrose - UC (110,00g, 12 h) in sucrose - SEC - UC (500g, 10 min) - UC (12,000g, 20 min) - UC (100,000g, 70 min) - UC (300g) - UC (3000g) - UF (0,45 $\mu$ m) - UC (110,000g, 80 min) - UF (0,2 $\mu$ m) - UC (110,000g, 75 min)	Blood	Breast cancer patients (128)	MDA-MB-231 MCF10CA1a 4T1 4T07		
- UC (500g, 10 min) - UC (12,000g, 20 min) - UC (100,000g, 70 min) - UC (300g) - UC (3000g) - UF (0,45 $\mu$ m) - UC (110,000g, 80 min) - UF (0,2 $\mu$ m) - UC (110,000g, 75 min)	Plasma	Breast cancer patients (22) Healthy individuals (6) Breast cancer patients (18 +48)	MDA-MB-231 organotropic lines	Integrins $\alpha_1$ , $\alpha_2$ , $\alpha_3$ , $\alpha_6$ , $\beta_1$ , $\beta_3$ , $\beta_4$ prognostic Integrins $\beta_3$ , $\beta_4$ , $\alpha_v\beta_5$ prognostic	[26]  [27]
- UC (300g, 10 min) - UC (2000g, 10 min) - UC (10,000g, 30 min) - UC [100,000g, 70 min (x2)] - UF (0,22 $\mu$ m) - UC (1500g, 20 min) - UC (16,000g, 45 min) - UC (100,000g, 2 h) - UF (0,22 $\mu$ m) - UC (300g, 5 min) - UC (2000g, 15 min) - UC (16,000g, 45 min) - UC (100,000g, 2 h) - UF (0,22 $\mu$ m) - UC (3000g, 10 min) - UC (15,000g, 35 min) - UF (100 kDa) (can be omitted) - UC [100,000g (x2)] <i>Alternatively</i> - UC (3000g, 10 min) - ExoQuick kit	Serum	Breast cancer patients (30)	T cells MDA-MB-231	PD-L1 diagnostic, treatment response PD-1 potentially prognostic	[34]  [35]
- UC (300g, 10 min) - UC (2000g, 10 min) - UC (10,000g, 30 min) - UC [100,000g, 70 min (x2)] - UF (0,22 $\mu$ m) - UC (1500g, 20 min) - UC (16,000g, 45 min) - UC (100,000g, 2 h) - UF (0,22 $\mu$ m) - UC (300g, 5 min) - UC (2000g, 15 min) - UC (16,000g, 45 min) - UC (100,000g, 2 h) - UF (0,22 $\mu$ m) - UC (3000g, 10 min) - UC (15,000g, 35 min) - UF (100 kDa) (can be omitted) - UC [100,000g (x2)] <i>Alternatively</i> - UC (3000g, 10 min) - ExoQuick kit	Blood	Breast cancer patients (46) Healthy individuals (20)	MDA-MB-231 MCF7 4T07 4T1  MDA-MB-231 MCF7	TGF $\beta$ R2 diagnostic (early), prognostic	[39]
- UC (300g, 10 min) - UC (2000g, 10 min) - UC (10,000g, 30 min) - UC [100,000g, 70 min (x2)] - UF (0,22 $\mu$ m) - UC (1500g, 20 min) - UC (16,000g, 45 min) - UC (100,000g, 2 h) - UF (0,22 $\mu$ m) - UC (3000g, 10 min) - UC (15,000g, 35 min) - UF (100 kDa) (can be omitted) - UC [100,000g (x2)] <i>Alternatively</i> - UC (3000g, 10 min) - ExoQuick kit	Serum	Breast cancer patients (30)	MDA-MB-231 MCF7	ADAM10 GLUT1 GPC1 potentially prognostic	[42]

Abbreviations: SEC = size-exclusion chromatography; UC = ultrafiltration; UF = ultrafiltration.

heterodimers composed of an  $\alpha$ - and a  $\beta$ -subunit [20]. Integrins on both the plasma membrane and extracellular vesicles' membrane actively contribute to several steps of cancer development [21–23].

A large-scale proteomic study showed that extracellular vesicles released from breast cancer cells expressed integrins  $\alpha_1$ ,  $\alpha_2$ ,  $\alpha_3$ ,  $\alpha_5$ ,  $\alpha_6$ ,  $\alpha_V$ ,  $\beta_1$ ,  $\beta_4$ , and  $\beta_5$ , and the level of integrins  $\alpha_1$ ,  $\alpha_6$ ,  $\alpha_V$ , and  $\beta_1$  in extracellular vesicles correlated with cancer stage [24]. The level of integrins  $\alpha_2$ ,  $\alpha_3$ ,  $\alpha_V$ , and  $\beta_1$  in extracellular vesicles correlated with the cell metastatic potential [25]. Additionally, the expression of integrin  $\alpha_V$  in plasma CD63-expressing extracellular vesicles correlated with cancer stage in both breast cancer patients and xenografted mice bearing metastatic tumors (Table 1) [25]. These findings suggested that the extracellular vesicles' integrin profile may be exploited as a prognostic biomarker.

A landmark study showed that the extracellular vesicles' integrin profile can be used as an organotropic biomarker to predict the metastasis site [26]. Organotropic cancer cells release extracellular vesicles with a unique integrin profile such that, when the extracellular vesicles were injected in nude mice, they exploited their integrin profile as an 'address code' to accumulate in the metastatic organ as their cells of origin and prepare pre-metastatic niches by targeting specific resident cells [26]. Extracellular vesicles expressing integrins  $\alpha_6\beta_4$  and  $\alpha_6\beta_1$  targeted fibroblasts and epithelial cells in the lungs, while extracellular vesicles expressing integrin  $\alpha_V\beta_5$  targeted Kupffer cells in the liver *in vivo* [26]. The expression of integrin  $\beta_4$  was higher in extracellular vesicles from a small cohort ( $n = 2$ ) of breast cancer patients that developed lung metastasis [27]. The association of the extracellular-vesicle expression of integrin  $\beta_4$  with lung metastasis was also confirmed in two cohorts of breast cancer patients in a recent study [27]. While several pieces of evidence indicate that breast cancer cells secrete extracellular vesicles with one or several integrins, the mechanisms to secrete exosomes with a specific integrin and how their relative proportions could direct exosomes toward a specific tissue or cells remain unclear.

### Immune checkpoint proteins

Immune checkpoint proteins are signaling pathway molecules expressed by immune cells to modulate immune responses while preserving self-tolerance [28]. Immune checkpoint proteins are either inhibitory or stimulatory [29]. Inhibitory immune checkpoint proteins have been detected in tumor cell-derived exosomes and it has been suggested that they are exploited by tumor cells to promote tumor progression and metastasis by inactivating cytotoxic T cells [30–32].

To date, only the level of the inhibitory immune checkpoint programmed death ligand 1 (PD-L1) from extracellular vesicles has been evaluated as a diagnostic tool in breast cancer. A positive correlation of serum level of extracellular vesicle PD-L1 with the stage of breast cancer was found by an electrochemical sensor [33]. HER2 is overexpressed in ~25% of breast cancers and is associated with poorest prognosis [34]. HER2-targeted drug resistance in HER2-positive breast cancer cells correlates with increased levels of the immunosuppressive molecules transforming growth factor  $\beta_1$  (TGF $\beta_1$ ) and PD-L1 [34]. However, the serum level of extracellular vesicle PD-L1 did not significantly associate with the response to HER2-targeted neoadjuvant therapy (trastuzumab with or without lapatinib) in a small cohort ( $n = 30$ ) of HER2<sup>+</sup> breast cancer patients [34]. Conversely, extracellular vesicle TGF $\beta_1$  — a molecule that regulates the expression of immune checkpoint proteins and co-expressed with PD-L1 on extracellular vesicles [32] — was significantly higher in patients who did not respond to the therapy compared with those who exhibited partial or complete response [34]. This would suggest that extracellular vesicle TGF $\beta_1$  might be a better outcome marker than extracellular vesicle PD-L1.

Activated cytotoxic T cells release extracellular vesicles expressing programmed cell death protein-1 (PD-1) (Table 1) that can restore immune surveillance in a breast cancer mouse model by PD-L1 internalization *via* clathrin-mediated endocytosis, and thereby prevent subsequent cellular PD-L1:PD-1 interaction [35]. Thus, the serum level of extracellular vesicle PD-1 secreted by T cells could be exploited as a tumor prognostic marker. It is worth noting that, unlike the continuous release of extracellular vesicles from cancer cells, the release of extracellular vesicles from T cells is triggered by rapid immune synapse during activation, which may make T-cell-derived extracellular vesicles difficult to detect and unreliable as prognostic tools [36–38]. A possible solution of this problem would be to detect extracellular vesicle PD-1 along with other immune checkpoint receptors.

### Growth factor receptors

A seminal report has shown that metastatic breast cancer cells release transforming growth factor- $\beta$  receptor-2 (TGF $\beta$ R2)-positive extracellular vesicles that promote tumor metastatic outgrowth and cytotoxic T-cell exhaustion *in vivo* [39]. The diagnostic and prognostic usefulness was also assessed on breast cancer patients ( $n = 46$ ). Patients with TNBC exhibited higher serum level of extracellular vesicle TGF $\beta$ R2 than both HER2<sup>+</sup> and luminal patients [39]. Additionally, the level of extracellular vesicle TGF $\beta$ R2 can be used as a biomarker for the early detection of metastasis with high sensitivity and specificity and predicts the overall and metastasis-free survival.

### Other surface proteins of serum extracellular vesicles

An *in vitro* study showed that the transmembrane proteins glucose transporter 1 (GLUT1), glypican 1 (GPC1), and a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) were expressed in the extracellular vesicles released by MDA-MB-231, a metastatic breast cancer cell line, but not MCF-10A, a noncancerous epithelial breast cell line, suggesting their potential diagnostic use as extracellular-vesicle biomarkers [40].

### Concluding remarks

There is solid scientific evidence to suggest that the surface proteomic profile of the extracellular vesicles isolated from the breast cancer patients' serum can be exploited to achieve information about, for instance, the cancer stage and malignant parameters as well as the outcome after neoadjuvant chemotherapy. The surface proteomic profile might be also exploited to achieve information about the parent cells and design novel cell-specific therapies, also with the aid of nanomedicine approaches [41,42]. However, many pieces of the puzzle are still missing to fully understand how to exploit the extracellular vesicles' surface proteomic profile as diagnostic, prognostic, and therapeutic biomarkers in breast cancer. One key point would be to understand how the body fluid from which the vesicles are isolated affects their surface proteomic profile. Currently, extracellular vesicles are described as released by parent cells equipped with the complete set of surface proteins (*native* surface proteins). However, numerous pieces of evidence have led to formulate the model that soluble proteins are added to the extracellular vesicles' surface from the extracellular milieu (*acquired* surface proteins or protein corona) (Figure 1) [3,43–47]. This would suggest that the body fluid, along with parent cells, can modulate the vesicles' surface proteomic landscape and, in turn, its use as a biomarker. However, the validation of this paradigm is currently hampered by the difficulty to preserve the protein corona during the isolation of extracellular vesicles [3]. An additional limitation derives from the fact that several distinct heterogeneous populations of extracellular vesicles are isolated by the different isolation methods [3]. The comparison of the biochemical properties of the extracellular vesicles obtained from different body fluids by using different isolation methods shall contribute to achieve the total retrieval of acquired surface proteins and support their use as biomarker tools in breast cancer.

### Data Availability

No data were used for the research described in this article.

### Declaration of Competing Interest

The authors of this article declare to have no disclosures or conflicting interests.

### Acknowledgements

This work was supported by the University of Rome Tor Vergata (2021 University Scientific Research Project) and the Italian Ministry of University and Research [2022 Program for Research Projects of National Interest (PRIN), Grant # 20229RMZZW].

### References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: **Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.** *CA Cancer J Clin* 2021, **71**:209–249.
  2. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJA: **Extracellular vesicles: biology and emerging therapeutic opportunities.** *Nat Rev Drug Discov* 2013, **12**:347–357.
  3. Ramos AP, Sebinelli HG, Ciancaglini P, Rosato N, Mebarek S, Buchet R, Millán JL, Bottini M: **The functional role of soluble proteins acquired by extracellular vesicles.** *J Extra Biol* 2022, **1**:e34.
- This review describes the current knowledge on how the corona of soluble proteins adsorbed on the extracellular vesicles' surface modulates the biological functions of the vesicles.
4. Bottini M, Mebarek S, Anderson KL, Strzelecka-Kiliszek A, Bozycki L, Simão AMS, Bolean M, Ciancaglini P, Pikula JB, Pikula S, et al.: **Matrix vesicles from chondrocytes and osteoblasts: their biogenesis, properties, functions and biomimetic models.** *Biochim Biophys Acta Gen Subj* 2018, **1862**:532–546.
  5. Naito Y, Yoshioka Y, Yamamoto Y, Ochiya T: **How cancer cells dictate their microenvironment: present roles of extracellular vesicles.** *Cell Mol Life Sci* 2017, **74**:697–713.
  6. Raposo G, Stoorvogel W: **Extracellular vesicles: exosomes, microvesicles, and friends.** *J Cell Biol* 2013, **200**:373–383.
  7. Novais AA, Tamarindo GH, Chuffa LGdA, Zuccari DAPdC: **Decoding hidden messengers: proteomic profiling of exosomes in mammary cancer research.** *Biomedicines* 2023, **11**:2839.
  8. Hemler ME: **Tetraspanin functions and associated microdomains.** *Nat Rev Mol Cell Biol* 2005, **6**:801–811.
  9. Wright MD, Moseley GW, van Spruiel AB: **Tetraspanin microdomains in immune cell signalling and malignant disease.** *Tissue Antigens* 2004, **64**:533–542.
  10. Andreu Z, Yáñez-Mó M: **Tetraspanins in extracellular vesicle formation and function.** *Front Immunol* 2014, **5**:442.
  11. Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, Xiao C, Ma K, Huang X, Li Y: **Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer.** *Mol Carcinog* 2019, **58**:674–685.
  12. Li S, Li X, Yang S, Pi H, Li Z, Yao P, Zhang Q, Wang Q, Shen P, Li X, et al.: **Proteomic landscape of exosomes reveals the functional contributions of CD151 in triple-negative breast cancer.** *Mol Cell Proteom* 2021, **20**:100121.
  13. Gerke V, Moss SE: **Annexins: from structure to function.** *Physiol Rev* 2002, **82**:331–371.
  14. Tomas A, Moss SE: **Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope.** *J Biol Chem* 2003, **278**:20210–20216.



15. van de Graaf SFJ, Hoenderop JGJ, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, Nilius B, Bindels RJM: **Functional expression of the epithelial Ca(2+) channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex.** *EMBO J* 2003, **22**:1478-1487.
16. Veschi EA, Bolean M, Strzelecka-Kiliszek A, Bandorowicz-Pikula J, Pikula S, Granjon T, Mebarek S, Magne D, Ramos AP, Rosato N, et al.: **Localization of annexin A6 in matrix vesicles during physiological mineralization.** *Int J Mol Sci* 2020, **21**:1367.
17. Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK: **Exosomal annexin II promotes angiogenesis and breast cancer metastasis.** *Mol Cancer Res* 2017, **15**:93-105.
18. Chaudhary P, Gibbs LD, Maji S, Lewis CM, Suzuki S, Vishwanatha JK: **Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.** *Breast Cancer Res* 2020, **22**:11-25.
19. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambain L, Poissonnier A, Ferraro GB, Baer C, et al.: **Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.** *Nat Cell Biol* 2019, **21**:190-202.
- This study reveals that AnxA6 expressed in circulating extracellular vesicles could be exploited as a predictive marker of metastasis and an outcome marker after neoadjuvant chemotherapy.
20. Hynes RO: **Integrins: bidirectional, allosteric signaling machines.** *Cell* 2002, **110**:673-687.
21. Cooper J, Giancotti FG: **Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance.** *Cancer Cell* 2019, **35**:347-367.
22. Mo Z, Cheong JYA, Xiang L, Le MTN, Grimson A, Zhang DX: **Extracellular vesicle-associated organotropic metastasis.** *Cell Prolif* 2021, **54**:e12948.
23. Paolillo M, Schinelli S: **Integrins and exosomes, a dangerous liaison in cancer progression.** *Cancers* 2017, **9**:95.
24. Hurwitz SN, Meckes DGJ: **Extracellular vesicle integrins distinguish unique cancers.** *Proteomes* 2019, **7**:14.
25. Zhang DX, Dang XTT, Vu LT, Lim CMH, Yeo EYM, Lam BWS, Leong SM, Omar N, Putti TC, Yeh YC, et al.:  **$\alpha$ v $\beta$ 1 integrin is enriched in extracellular vesicles of metastatic breast cancer cells: a mechanism mediated by galectin-3.** *J Extra Vesicles* 2022, **11**:e12234.
26. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tescic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al.: **Tumour exosome integrins determine organotropic metastasis.** *Nature* 2015, **527**:329-335.
- This study reveals that circulating tumor-derived extracellular vesicles display a unique integrin profile that may be useful not only to predict the propensity to metastasize but also to determine the site(s) of future metastasis.
27. Grigoryeva ES, Tashireva LA, Savelieva OE, Zavyalova MV, Popova NO, Kuznetsov GA, Andryuhova ES, Perelmutter VM: **The association of integrins  $\beta$ 3,  $\beta$ 4, and  $\alpha$ V $\beta$ 5 on exosomes, CTCs and tumor cells with localization of distant metastasis in breast cancer patients.** *Int J Mol Sci* 2023, **24**:2929.
28. Abril-Rodríguez G, Ribas A: **SnapShot: immune checkpoint inhibitors.** *Cancer Cell* 2017, **31** (848-848.e1).
29. Sharma P, Allison JP: **Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.** *Cell* 2015, **161**:205-214.
30. Xing C, Li H, Li R-J, Yin L, Zhang H-F, Huang Z-N, Cheng Z, Li J, Wang Z-H, Peng H-L: **The roles of exosomal immune checkpoint proteins in tumors.** *Mil Med Res* 2021, **8**:56.
31. Pardoll DM: **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer* 2012, **12**:252-264.
32. Daassi D, Mahoney KM, Freeman GJ: **The importance of exosomal PDL1 in tumour immune evasion.** *Nat Rev Immunol* 2020, **20**:209-215.
33. Cao Y, Wang Y, Yu X, Jiang X, Li G, Zhao J: **Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks.** *Biosens Bioelectron* 2020, **166**:112452.
34. Martinez VG, O'Neill S, Salimu J, Breslin S, Clayton A, Crown J, O'Driscoll L: **Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.** *Oncoimmunology* 2017, **6**:e1362530.
35. Qiu Y, Yang Y, Yang R, Liu C, Hsu J-M, Jiang Z, Sun L, Wei Y, Li C-W, Yu D, et al.: **Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.** *Oncogene* 2021, **40**:4992-5001.
- This study reveals that PD-1 secreted in an vesicular form from tumor-associated T cells hampers the antitumor function of PD-L1 in TNBC and suggests a potential avenue for modifying the surface of therapeutic extracellular vesicles with inhibitory immune checkpoint receptors.
36. Calvo V, Izquierdo M: **Inducible polarized secretion of exosomes in T and B lymphocytes.** *Int J Mol Sci* 2020, **21**:2631.
37. Ventimiglia LN, Alonso MA: **Biogenesis and function of T cell-derived exosomes.** *Front Cell Dev Biol* 2016, **4**:84.
38. Gutiérrez-Vázquez C, Villarroya-Beltri C, Mittelbrunn M, Sánchez-Madrid F: **Transfer of extracellular vesicles during immune cell-cell interactions.** *Immunol Rev* 2013, **251**:125-142.
39. Xie F, Zhou X, Su P, Li H, Tu Y, Du J, Pan C, Wei X, Zheng M, Jin K, et al.: **Breast cancer cell-derived extracellular vesicles promote CD8(+) T cell exhaustion via TGF- $\beta$  type II receptor signaling.** *Nat Commun* 2022, **13**:4461.
40. Risha Y, Minic Z, Ghobadloo SM, Berezovski MV: **The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.** *Sci Rep* 2020, **10**:13572.
41. Bottini M, Sacchetti C, Pietroiusti A, Bellucci S, Magrini A, Rosato N, Bottini N: **Targeted nanodrugs for cancer therapy: prospects and challenges.** *J Nanosci Nanotechnol* 2014, **14**:98-114.
42. Stavrou A, Ortiz A: **Extracellular vesicles: a novel tool in nanomedicine and cancer treatment.** *Cancers* 2022, **14**:4450.
43. Radeghieri A, Bergese P: **The biomolecular corona of extracellular nanoparticles holds new promises for advancing clinical molecular diagnostics.** *Expert Rev Mol Diagn* 2023, **23**:471-474.
44. Musicò A, Zenatelli R, Romano M, Zandrini A, Alacqua S, Tassoni S, Paolini L, Urbinati C, Rusnati M, Bergese P, et al.: **Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable".** *Nanoscale Adv* 2023, **5**:4703-4717.
45. Tóth EÁ, Turiák L, Visnovitz T, Cserép C, Mázló A, Sódar BW, Försönits AI, Petővári G, Sebestyén A, Komlósi Z, et al.: **Formation of a protein corona on the surface of extracellular vesicles in blood plasma.** *J Extra Vesicles* 2021, **10**:e12140.
46. Heidarzadeh M, Zarebkohan A, Rahbarghazi R, Sokullu E: **Protein corona and exosomes: new challenges and prospects.** *Cell Commun Signal* 2023, **21**:64.
47. Radeghieri A, Alacqua S, Zandrini A, Previcini V, Todaro F, Martini G, Ricotta D, Bergese P: **Active antithrombin glycoforms are selectively physisorbed on plasma extracellular vesicles.** *J Extra Biol* 2022, **1**:e57.